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Figure 1.
Subclassification of childhood ALL. Blue wedges refer to B-progenitor ALL, yellow to
recently identified subtypes of B-ALL, and red wedges to T-lineage ALL
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anuscriptchildren (median age, 9 years; Figure 1B) with BCP-ALL. Strik-
ingly, it is associated with a dismal outcome, with a high risk of both
early and late relapses, when patients are treated as standard risk.
Outcome is dramatically improved when these patients are treated
on high-risk regimens (Figure 2A).7
IGH@ translocations. A range of genes have been reported as
translocation partners of the immunoglobulin heavy chain locus
IGH@, including the gene encoding cytokine receptor-like factor 2
(CRLF2, also known as thymic stromal lymphopoietin receptor,
TLSPR), the CCAAT enhancer-binding protein (CEBP) family of
transcription factors, the DNA-binding protein inhibitor ID4, the
cytokine receptor for erythropoietin (EPOR), and the microRNA
miR-125b.8 Although, currently, there appears to be no functional link
between these partners, IGH@ translocations predominate in adoles-
cents and young adults (Figure 1B) and are associated with an inferior
survival.4
Association of chromosomal abnormalities with age
Although virtually all chromosomal abnormalities occur in both
childhood and adult ALL, as indicated for some of the specific
abnormalities in the above section, there is a significant difference
in incidence of most cytogenetic subgroups according to age, as
shown in Figure 1B. For example, MLL rearrangements [including
t(4;11)(q21;q23) and other MLL rearrangements] dominate in
infants up to 1 year of age; ETV6-RUNX1 and high hyperdiploidy
predominate in young children, with very few ETV6-RUNX1 adult
cases, whereas the incidence of BCR-ABL1 increases dramatically
with age.
The biological differences, including variance in cooperating ge-
netic abnormalities, behind these diverse distributions likely influ-
ence outcome, because survival rates for adult patients within each




The majority of chromosomal abnormalities described in “Cytoge-
netic subgroups and outcome” are considered to be primary genetic
changes driving leukemia initiation, with additional genetic events
required for the development of overt ALL. Genomic studies and
next-generation sequencing (targeted and genome wide) have
revealed the presence of many additional genetic abnormalities. In
BCP-ALL, rearrangements involving CRLF2 are found in !6% of
childhood and adult BCP-ALL,4,9 although they are more prevalent
in Down syndrome (54%). In addition to the translocation IGH@-
CRLF2, deletions within the pseudoautosomal region (PAR1) of the
sex chromosomes results in the fusion, P2RY8-CRLF2. Both rearrange-
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Figure 1. Distribution of cytogenetic abnormalities from data collected from UK childhood ALL treatment trials. (A) Relative incidence of the
established cytogenetic abnormalities among childhood BCP-ALL. (B) Distribution of different cytogenetic subgroups according to age. The
abnormalities are color coded and the incidence of each abnormality indicated according to age group. The relative incidence of T-ALL is also shown.
IGH@ indicates all translocations except with CRLF2; CRLF2, IGH@-CRLF2 and P2RY8-CRLF2; hap/hypo, hypodiploidy (" 44 chromosomes);
t(9;22), BCR-ABL1 positive; and HeH, high hyperdiploidy.
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children (median age, 9 years; Figure 1B) with BCP-ALL. Strik-
ingly, it is associated with a dismal outcome, with a high risk of both
early and late relapses, when patients are treated as standard risk.
Outcome is dramatically improved when these patients are treated
on high-risk regimens (Figure 2A).7
IGH@ translocations. A range of genes have been reported as
translocation partners of the immunoglobulin heavy chain locus
IGH@, including the gene encoding cytokine receptor-like factor 2
(CRLF2, also known as thymic stromal lymphopoietin receptor,
TLSPR), the CCAAT enhancer-binding protein (CEBP) family of
transcription factors, the DNA-binding protein inhibitor ID4, the
cytokine receptor for erythropoietin (EPOR), and the microRNA
miR-125b.8 Although, currently, there appears to be no functional link
between these partners, IGH@ translocations predominate in adoles-
cents and young adults (Figure 1B) and are associated with an inferior
survival.4
Association of chromosomal abnormalities with age
Although virtually all chromosomal abnormalities occur in both
childhood and adult ALL, as indicated for some of the specific
abnormalities in the above section, there is a significant difference
in incidence of most cytogenetic subgroups according to age, as
shown in Figure 1B. For example, MLL rearrangements [including
t(4;11)(q21;q23) and other MLL rearrangements] dominate in
infants up to 1 year of age; ETV6-RUNX1 and high hyperdiploidy
predominate in young children, with very few ETV6-RUNX1 adult
cases, whereas the incidence of BCR-ABL1 increases dramatically
with age.
The biological differences, including variance in cooperating ge-
netic abnormalities, behind these diverse distributions likely influ-
ence outcome, because survival rates for adult patients within each




The majority of chromosomal abnormalities described in “Cytoge-
netic subgroups and outcome” are considered to be primary genetic
changes driving leukemia initiation, with additional genetic events
required for the development of overt ALL. Genomic studies and
next-generation sequencing (targeted and genome wide) have
revealed the presence of many additional genetic abnormalities. In
BCP-ALL, rearrangements involving CRLF2 are found in !6% of
childhood and adult BCP-ALL,4,9 although they are more prevalent
in Down syndrome (54%). In addition to the translocation IGH@-
CRLF2, deletions within the pseudoautosomal region (PAR1) of the
sex chromosomes results in the fusion, P2RY8-CRLF2. Both rearrange-
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Figure 1. Distribution of cytogenetic abnormalities from data collected from UK childhood ALL treatment trials. (A) Relative incidence of the
established cytogenetic abnormalities among childhood BCP-ALL. (B) Distribution of different cytogenetic subgroups according to age. The
abnormalities are color coded and the incidence of each abnormality indicated according to age group. The relative incidence of T-ALL is also shown.
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children (median age, 9 years; Figure 1B) with BCP-ALL. Strik-
ingly, it is associated with a dismal out ome, h gh risk of both
early and late relapses, when patients are tr ated as st ndard risk.
Outcome is dramatically improved when hese patients are treated
on high-risk regimens (Figure 2A).7
IGH@ translocations. A range of genes have been r p rted as
translocation partners of the immunoglobulin heavy chain locus
IGH@, including the gene encoding cytokine receptor-like factor 2
(CRLF2, also known as thymic tromal lymphopoietin receptor,
TLSPR), the CCAAT enhancer-binding protein (CEBP) family of
transcription factors, the DNA-bi ding protein inhibitor ID4, the
cytokine receptor for er hropoietin (EPOR), and the microRNA
miR-125b.8 Although, currently, there appears to be o functional link
between these partners, IGH@ translocatio s predominate in adoles-
cents and young adults (Figure 1B) and are associated with an inferior
survival.4
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Table	  2.	  Gene+c	  altera+ons	  in	  B-­‐ALL:	  transloca+ons	  and	  genic	  altera+ons.	  Table	  modiﬁed	  of	  (2)	  (3)	  (5)	  (6)	  (7)	  (8)	  
Figure	  2.	  Subclassiﬁca+on	  of	  childhood	  ALL.	  Blue	  wedges	  refer	  to	  B-­‐progenitor	  
ALL,	  yellow	  to	  recently	  iden+ﬁed	  subtypes	  of	  B-­‐ALL,	  and	  red	  wedges	  to	  T-­‐lineage	  
ALL.	  B-­‐ALL	  correspond	  to	  the	  85%	  and	  T-­‐ALL	  to	  the	  15%	  of	  all	  cases.	  (2)	  
	  	  
Figure	  1.	  Distribu+on	  of	  diﬀerent	  cytogene+c	  
subgr ups	  according	  to	  age.	  (1)	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Aim	  of	  the	  project	  
The	   aim	   of	   this	   project	   is	   do	   a	   review	   of	   the	  main	   gene+c	   altera+ons	   in	  
pediatric	  ALL	  and	  its	  prognosis,	  using	  ar+cles	  published	  between	  2012	  and	  
2015	  and	  searched	  in	  PubMed.	  
Table	  1.	  Gene+c	  altera+ons	  in	  B-­‐ALL:	  aneuploidy.	  Table	  modiﬁed	  of	  (3)	  (4)	  
Acute	   Lymphoblas+c	   Leukemia	   (ALL)	   is	   a	  malignant	   clonal	   prolifera+on	   of	  
precursor	  limphoid	  cells,	  B	  and	  T.	  	  
	  
Despite	   this	   hematologic	   tumour	   can	   occur	   at	   all	   ages,	   it	   is	   the	   most	  
prevalent	   malignancy	   in	   childhood	   and	   it	   has	   a	   preponderance	   in	   males	  
over	   females.	   Speciﬁcally,	   in	   Spain	   it	   comprised	   28,5%	   of	   childhood	  
malignancies	  between	  1983	  and	  2002.	  
	  
ALL	   is	   a	  mul+step	   process	   associated	  with	   the	   acquisi+on	   of	   gene<c	   and	  
epigene<c	   altera<ons	   in	   the	   leukemic	  blast	   cells,	   that	   varies	   according	   to	  
the	  age	  (Figure	  1),	  and	  it	  is	  a	  heterogeneous	  disease	  composed	  of	  mul+ple	  
biological	  subgroups.	  (Figure	  2)	  
	  
Prolifera+on	  and	  accumula+on	  of	  blasts	  cells	  in	  the	  bone	  marrow	  results	  in	  
a	   suppression	   of	   hematologic	   processes,	   causing	   symptoms	   that	   reﬂect	  
bone	   marrow	   failure	   (pancytopenia),	   as	   anaemia,	   thrombocytopenia	   and	  
neutropenia.	  
It	   can	   be	   dis+nguished	   diﬀerent	   methods	   of	   diagnosis.	   Firstly,	   the	  
morphological	  diagnosis	   is	  made	  with	  an	  assessment	  of	  the	  bone	  marrow.	  
Secondly,	  it	  is	  important	  ﬂow	  cytometry,	  that	  is	  the	  standard	  procedure	  for	  
ALL	   diagnos+c	   	   and	   subclassiﬁca+on	   and	   also	   allows	   to	   detect	   minimal	  
residual	   disease.	   In	   addi+on,	   cytogene+cs,	   FISH	   and	   karyotyping,	   are	   an	  
important	   step	   in	   ALL	   classiﬁca+on	   because	   conven+onal	   karyotyping	   can	  
be	  helpful	   in	   iden+ﬁca+on	  of	  recurrent	  transloca+ons	  and	  gain	  and	  loss	  of	  
chromosomal	   material.	   Next-­‐genera+on	   sequencing	   approaches	   are	  
important	   to	   comprehensively	   iden+fy	   gene+c	   altera+ons	   in	   th 	   genome	  
and	  transcriptome.	  	  
Figure	  3.	  Diﬀerent	  types	  of	  epigene+c	  modiﬁca+ons,	  as	  DNA	  me+la+on,	  histone	  modiﬁca+on,	  miRNA	  altera+ons	  
	  	  





High	  Hyperdiploidy	   51-­‐67	   25-­‐30	   Good	  outcome	  
Low	  Hyperdiploidy	   47-­‐50	   -­‐	   Poor	  outcome	  
Hypodiploidy	   <46	   5-­‐8	   Good	  outcome	  with	  45	  chromosomes	  
and	  poor	  outcome	  with	  <45,	  especially	  
with	  33	  to	  44	  chromosomes	  
Near	  Haploidy	   23-­‐29	   0,7-­‐	  2,4	   Poor	  outcome	  
Type	  of	  
Altera<on	   Aﬀected	  Genes	   Locus	   Func<onal	  Conseque ces	   Prevalence	  (%)	   Prognosis	  
Recurrent	  
t nsloc +ons	  	   ETV6-­‐RUNX1	   t(12;21)(p13;q22)	   Altered	  expression	  of	  RUNX1	  regulated	  genes	   25	   Good	  outcome	  
BCR-­‐ABL1	   t(9;22)(q34;q11)	   Cons+tu+ve	  tyr sin-­‐kina e	  protein	  ac+va+on	   3-­‐5	   Poor	  outcome	  
MLL-­‐partners	   (11q23)	   MLL	  codiﬁes	  a	  me+ltransferase-­‐histone	  required	  f r	  hematopoie+c	  regula+on	   80%	  in	  <1	  year;	  10%	  children	   Poor	  outcome	  
TCF3/E2A-­‐PBX1	   t(1;19)(q23;p13)/	  der(19)t(1;19)(q23;p13)	   Anormal	  PBX1	  ac+va+on	  and	  transac+va+on	  of	  diﬀerent	  genes	   6	   Poor	  outcome	  	  
IGH@	   14q32	   Juxt posi+on	  of	  IGH@	  elements	  with	  transcrip+on	  factor	  and	  cytokine	  receptor	   <5	   Poor	  outcome	  
BCR-­‐ABL1-­‐lik 	   -­‐	  	   IKZF1	  and	  CDN2A/B	  dele+ons,	  JAK2	  muta+ons,	  CRLF2	  rearrangements	   10-­‐12	   Poor	  outcome	  
Genic	  
altera+ons	  	   CRLF2	   PAR1	  (Xp22.3)/(Yp11.3)	   IKZF1	  altera+on,	  JAK1	  muta+on,	  implies	  cons+tu+ve	  STAT	  pathway	  ac+va+on	  	   5-­‐7	   Poor	  outcome	  
iAMP21	   Intrachromosomal	  ampliﬁca+on	  of	  cr21	   3	  or	  more	  copies	  of	  RUNX1	  	   2	   Poor	  outcome	  
IKZF1	   7p12.2	   Loss	  of	  func+on	  of	  IKAROS	  transcrip+on	  factor	   14	   Poor	  outcome	  
JAK1/2	   (1p32.3-­‐p31.3)/(9p24)	   Altera+on	  of	  cytokine	  signalling	  and	  asoc at d	  with	  IKZF1	  and	  CDKN2A/B	  
muta+on	  
10	   Increased	  risk	  of	  LLA	  
PAX5	   (9p13)	   Inac+va+ng	  muta+on	  of	  the	  transcrip+on	  factor	  	   32	   No	  impact	  
TP53	   (17q13.1)	   Loss	  of	  tumour	  suppression	  ge es	  func+on	  	   3	   Poor	  outcome	  
CREBBP	   16p13.3	   Altera+on	  of	  transcrip+onal	  regula+on	  	   19%	  relapses	   -­‐	  	  
Approximately	   75%	   of	   childhood	   ALL	   cases	   have	   recurrent	   gene+c	  
abnormali+es,	   including	   aneuploidy,	   chromosomal	   arrangements	   and	  
submicroscopic	  DNA	  muta+ons.	  
Childhood	  ALL	  is	  considered	  a	  sporadic	  disease,	  but	  predisposi+on	  exists	  in	  <5%	  
of	  cases,	  as	  occurs	  in	  Down	  Syndrome.	  Pa+ents	  with	  this	  syndrome	  have	  20-­‐fold	  
increased	  incidence	  of	  ALL.	  
	  
It	   is	  noteworthy	  that	  many	  of	  the	   involved	  genes	  are	  related	  with	  key	  roles	   in	  
lymphoid	  development,	  cell	  cycle	  regula+on	  and	  tumour	  suppression,	  apoptosis	  
regulators,	   lymphoid	   signalling,	   transcrip+onal	   regulators,	   and	   	   chroma+n	  
structure	  and	  epigene+c	  regulators.	  
	  
In	   B-­‐ALL	   should	   be	   highlighted	   numerical	   abnormali<es,	   that	   may	   involve	  
ploidy	   changes	   or	   gain	   or	   loss	   of	   individual	   chromosomes	   (aneuploidy).	   It	   is	  
important	   that	   ploidy	   is	   considered	   an	   impera+ve	   rognos+c	   fac or	   in	  
childhood	   ALL.	   In	   this	   type	   of	   altera+ons,	   it	   can	   be	   dis+nguished	   hight	  
hiperdiploidy,	  low	  hiperdiploidy,	  hipodiploidy	  and	  near	  haploidy.	  (Table	  1)	  
Furthermore,	  there	  are	  recurrent	  transloca<ons,	  such	  as	  ETV6-­‐RUNX1	  and	  MLL	  
with	   diﬀerent	   partners,	   and	   genic	   altera<ons,	   such	   as	   iAMP21	   or	   PAX5	  
muta+on.	  (Table	  2)	  
	  
T-­‐ALL	   is	   characterized	   by	   a	   worse	   prognosis	   compared	   to	   B-­‐ALL.	   In	   this	  
subgroup	   there	  are	  also	   transloca+ons	   involving	  T-­‐receptor	  and	   chromosomal	  
and	  subchromosomal	  altera+ons.	  Early-­‐T	  precursor	  is	  a	  new	  subgroup	  in	  T-­‐ALL	  
that	  has	  10%	  frequency	  and	  a	  poor	  outcome.	  	  
	  
Finally,	   there	   are	   also	   important	   epigene<c	   altera<ons,	   as	   DNA	   me+la+on,	  
histone	  modiﬁca+on	  and	  miRNA	  altera+ons.	   In	   this	   cases	   the	  primary	   gene+c	  
sequence	   is	  normal	  but	   there	  are	  other	   factors	   that	  aﬀect	  gene	  expression.	   It	  
should	   be	   noted	   that	   are	   reversible	   events	   that	   could	   be	   targeted	   with	  












It	  can	  disrupt	  key	  molecular	  pathways,	  such	  as	  apoptosis	  
and	  DNA	  repair	  pathways.	  There	  re	  diﬀerent	  proﬁles	  
correlated	  with	  biological	  ALL	  subtypes	  
Histone	  modiﬁca+ons	   The	  most	  prominent	  are	  me+la+on	  and	  ace+la+on	  and	  can	  directly	  aﬀect	  gene	  transcrip+on	  
miRNA	  altera+ons	  
They	  play	  a	  cri+cal	  role	  in	  targe+ng	  mRNAs	  for	  cleavage	  or	  
transla+onal	  repression.	  Their	  alteracion	  can	  aﬀect	  to	  cri+cal	  
regula+ona	  pathways	  
Epigene+c	  Modiﬁca+ons	  
In	   this	   kind	   of	   cancer	   predominate	   B-­‐progenitor	   tumours,	   with	   gene+c	   and	   epigene+c	  
altera+ons.	  It	  is	  important	  to	  have	  in	  mind	  that	  with	  the	  analysis	  and	  the	  risk	  stra+ﬁca+on	  in	  
func+on	  of	   gene+c	  altera+ons	   it	   can	  be	  made	  a	  prognosis	   approxima+on	  with	   the	   aim	   to	  
administrate	  the	  best	  therapy.	  	  
	  
As	   this	   kind	  of	   cancer	   is	   the	  most	   frequent	   in	   childhood,	   it	  will	   be	   successful	   to	   carry	  out	  
studies	  to	  improve	  diagnos+c	  and	  therapeu+c	  approaches.	  
	  
